Tratamiento antirretroviral de inicio en pacientes infectados por el virus de la inmunodeficiencia humana en España: decisiones con relación a características inmunovirológicas específicas (estudio PERFIL-es) |
| |
Authors: | Pompeyo Viciana Antonio Ocampo Henar Hevia Marta Palazuelos Francisco Ledesma |
| |
Institution: | 1. Servicio Enf. Infecciosas, Hospital Universitario Virgen del Rocío, Sevilla, España;2. Unidad VIH. Med. Interna, Hospital Xeral Cíes, Vigo, España;3. Medical Affairs Manager, Janssen, Madrid, España |
| |
Abstract: | IntroductionThe purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice.MethodsAn observational restrospective study performed in 65 Spanish hospitals.ResultsWas a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count < 350 cells/μl.ConclusionThe initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|